A plan built around expanding the traditional evaluator pipeline, without first testing what AI can absorb, risks locking in permanent headcount and cost against a workload that may shrink or radically change.
A review recommendation that should be reconsidered because of time
September 8, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
September 10, 2026 - - Latest News -
Which is it? The two perspectives on patient input compounded by the lack of transparency
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News -
Guilt over this enduring failure is the correct response
September 9, 2026 - - Latest News -
Poweroos chase world title in Argentina with new backing from Biogen
September 9, 2026 - - Latest News -
What will AI be capable of in two months? We don't know, and that's the point
September 9, 2026 - - Latest News
